{'fraction_non_alphanumeric': 0.023035230352303523, 'fraction_numerical': 0.008130081300813009, 'mean_word_length': 5.482456140350878, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An update on pre‐eclampsia prediction research

Key content: • Early prediction of future pre-eclampsia risk includes ultrasound assessment of uterine perfusion, angiogenic vascular markers and fetal nucleic acids. • Angiogenic markers such as soluble fms-like tyrosine kinase-1, soluble endoglin, vascular endothelial growth factor 165b and fetal nucleic acids show altered levels in women who develop pre-eclampsia, well before the onset of symptoms. • In future years it may be possible to offer women of 12 weeks of gestation a combined screening test involving quantification of fetal nucleic acids and angiogenic markers and ultrasound assessment of uterine pulsatility index to quantify accurately their overall pre-eclampsia risk.